ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sandoz Buys Maker Of Dermatology Drugs

by Michael McCoy
May 7, 2012 | APPEARED IN VOLUME 90, ISSUE 19

Novartis’ Sandoz unit will acquire Fougera Pharmaceuticals, a specialty dermatology generics company, for $1.5 billion in cash. Fougera is the former dermatology division of Nycomed, the rest of which was acquired last year by Takeda Pharmaceutical. Based in Melville, N.Y., Fougera had 2011 sales of $429 million. Sandoz says the purchase will make it the world’s number one generic dermatology medicines company with annual sales of about $620 million, primarily in the U.S.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment